

The Three TCRA Assumptions

The TCRA plan rests on three assumptions.

The first assumption is that BIG4 will decide to employ TCRA intellectual property in next generation clinical lab analyzers worldwide and thereby collect up to **\$1 trillion** of royalty cash flow for TCRA shareholders over the life of the TCRA patents.

The second assumption is that BIG4 will announce their plans for deploying DLA worldwide to achieve immediate PV for their future **\$320 billion** cash flow.

The third assumption: is that post BIG4's DLA announcements each TCRA share will sell for **\$250,000** at a TCRA company value of **\$300 billion**.

2025 Version

The TCRA plan rests on three assumptions.

The first assumption is that, highly motivated, the Big Four are powerful enough to replace their current TLA automation with patented DLA in their clients clinical labs worldwide and manage the collection of up to **\$1 trillion** of royalty cash flow for TCRA shareholders over the life of the TCRA patents.

The second assumption is that when the BIG4 announce their intention to replace TLA with DLA, TCRA company valuation will be more than **\$300 billion** based on investor confidence that the BIG4 can create **\$1 trillion** future free cash flow for TCRA shareholders and that then immediately raise **\$20 billion** for WIRhE and others.

The third assumption is that as soon as BIG4 understand the TCRA deal structure and their own immediate **\$320 billion** cash flow benefit, they will make the DLA announcements.

VVVVVVV

C